Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: results of the Multicentre All Ireland Immunotherapy Study Group.

Rogers, E

Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: results of the Multicentre All Ireland Immunotherapy Study Group. [electronic resource] - European urology Mar 2000 - 261-6 p. digital

Publication Type: Clinical Trial; Journal Article; Multicenter Study

0302-2838

10.1159/000052353 doi


Carcinoma, Renal Cell--drug therapy
Feasibility Studies
Female
Humans
Injections, Subcutaneous
Interferon Type I--administration & dosage
Interleukin-2--administration & dosage
Kidney Neoplasms--drug therapy
Male
Middle Aged
Recombinant Proteins--administration & dosage
Risk Factors
Survival Rate